Ekaterina (Kat) Cleary, PhD, is Lead Data Analyst at the Center for Integration of Science and Industry and an Adjunct Professor of Mathematical Sciences at Bentley University, where she teaches Data Visualization. She received her BS in Biology/Bioinformatics from UMass Lowell and MS degree in Bioinformatics from Boston University. She holds a PhD in Biomedical Engineering and Biotechnology from UMass Lowell, where her thesis work focused on statistical modeling of environmental risk factors influencing cognitive decline. Her current research examines the public sector’s contribution to the science underlying drug discovery, as well as the public value created from this science. Her recent publication on the “Contribution of NIH funding to new drug approvals 2010–2016” has informed legislation to address fair prices on drugs supported by taxpayer funded research.

By this expert

US Tax Dollars Funded Every New Pharmaceutical in the Last Decade

Article | Sep 2, 2020

Amid debates over costs—and profits—from a coronavirus vaccine, a new study shows that taxpayers have been footing the bill for every new drug approved between 2010 and 2019

Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010–2019

Paper Working Paper Series | | Sep 2020

Amid debates over costs—and profits—from a coronavirus vaccine, a new study shows that taxpayers have been footing the bill for every new drug approved between 2010 and 2019

Big Pharma Wants to Pocket the Profits From a COVID Treatment You Already Paid For

Article | Jul 7, 2020

Gilead’s shareholders want exorbitant profits from Remdesivir, even though it was the public that enabled its development.

The Fleming Myth and the Public Sector Contribution to Discovery and Development of New Cancer Drugs

Article | Jun 2, 2020

Abstract, “basic science” research is essential to drug discovery. It is also largely funded by the public sector.